Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
NCT05009979Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of piflufolastat f 18 in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Started Jan 2023; status: terminated.
02
Drugs
piflufolastat f 18
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05009979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05009979.